A Study of Viracept in AIDS Patients With Cytomegalovirus Retinitis

Phase 2

Completed

• Conditions: Cytomegalovirus Retinitis; HIV Infections

• Registration Number: NCT00002169
• Lead Sponsor: Agouron Pharmaceuticals

Brief Summary

The purpose of this study is to see if it is safe and effective to give Viracept to AIDS patients who are already being treated for cytomegalovirus (CMV) retinitis.

Detailed Description

Not available

Study Timeline

• Status Verified: 1999-05
• Study First Submitted: 1999-11-02
• Study First Submitted QC: 2001-08-30
• Study First Posted: 2001-08-31
• Last Update Submitted: 2005-06-23
• Last Update Posted: 2005-06-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: Not specified

Trial Locations

Locations (8)

Univ of Texas Med Branch; 🇺🇸 Galveston, Texas, United States

Univ of California / San Diego Treatment Ctr; 🇺🇸 San Diego, California, United States

Univ of Southern California / LA County USC Med Cntr; 🇺🇸 Los Angeles, California, United States

Harbor UCLA Med Ctr; 🇺🇸 Torrance, California, United States

Univ of California / UCI Med Ctr; 🇺🇸 Orange, California, United States

George Washington Univ; 🇺🇸 Washington, District of Columbia, United States

Northwestern Univ / SOCA; 🇺🇸 Chicago, Illinois, United States

Baylor Univ; 🇺🇸 Houston, Texas, United States